ANTI-SARS-CoV-2 S ELECSYS 200T ROCHE

Immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) spike (S) protein receptor binding domain (RBD) in human serum and plasma. The test is intended as an aid to assess the adaptive humoral immune response to the SARS‑CoV‑2 S protein.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.

» </ span> mRNA vaccines such as the one from Pfizer, which is already administered in our country, carry a single-stranded messenger RNA with a 5 ‘end cap, produced using free in vitro transcription cells from the corresponding DNA standards, encoding the viral spike protein ( S) of SARS-</ CoV-2 .
Double-antigen sandwich principle.      »Total duration of assay: 18 minutes.

▪ 1st incubation: 20 µL of sample, biotinylated SARS‑CoV‑2 S‑RBD‑specific recombinant antigen and SARS‑CoV‑2 S‑RBD‑specific recombinant antigen labeled with a
ruthenium complexa) form a sandwich complex.
▪ 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
▪ The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces
chemiluminescent emission which is measured by a photomultiplier.
▪ Results are determined via a calibration curve which is instrumentspecifically generated by 2‑point calibration and a master curve provided via the reagent barcode or e‑barcode.